A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions

A Prospective, Randomised, Open Label, Single Dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study of Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Tablets (Synthon Hispania SL, Spain) Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets (Astellas Pharma Europe B.V., the Netherlands), in Healthy Adult Male Subjects, Under Fasting Conditions

The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single dose administration in healthy adult male subjects under fasting conditions.

Study Overview

• Status: Recruiting
• Conditions: Healthy Volunteer Male Subjects
• Intervention / Treatment: Drug: Tamsulosin (0.4 mg/j); Drug: Tamsulosin (0.4 mg/j)

Detailed Description

In this Phase I study, the test medication Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain) is compared to the reference medication (Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets by Astellas Pharma Europe B.V., the Netherlands) in terms of bioequivalence of the the tested formulations under fasting conditions.

• Study Type: Interventional
• Enrollment (Estimated): 46
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Kai Schumacher, MD; Phone Number: 2357 +49 (0)30 6707; Email: kaischumacher@berlin-chemie.de
• Study Contact Backup: Name: Anja Pagenkopf; Phone Number: 2878 +49 6707; Email: apagenkopf@berlin-chemie.de

Study Locations

• Armenia
  • Ankuk Region
    • Yerevan, Ankuk Region, Armenia, 0037
      • Recruiting
      • "Tonus-Les" LLC
      • Contact: Shougher Heboyan, MD; Phone Number: 67 +374 936656; Email: shogherheboyan@mail.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Capable of understanding the informed consent form (ICF) and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
2. Healthy male subjects aged 18 to 45 years inclusive, at the time of signing the ICF, able to tolerate venipuncture.
3. Verified diagnosis of being "healthy" according to results of standard clinical, laboratory and instrumental methods of examination.
4. Body weight ≥50 kg and ≤ 120 kg, Body Mass Index between ≥18.5 and ≤30.0 kg/m2.
5. Non-smokers (for at least 3 months).
6. Subjects should be willing to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraception during participation in the study and for 30 days thereafter. Double-barrier contraceptive method: condom used together with spermicidal foam/gel/film/cream/suppository.

Exclusion Criteria:

1. History or presence of allergies.
2. Known hypersensitivity or intolerance to tamsulosin and/or other alpha 1 adreno-receptor antagonists and/or any other excipient of the study drugs.
3. History of drug-induced angioedema.
4. History, presence or necessity of glaucoma or cataract surgery.
5. History or presence of acute or chronic diseases of cardiovascular (including arterial hypotension), bronchopulmonary, nervous, endocrine, reproductive systems (including ejaculation disorders), and also diseases of the gastrointestinal tract, liver (including hepatic insufficiency), urinary tract and kidneys (including renal insufficiency), blood, mental diseases; history of convulsive attacks.
6. Acute infectious diseases (e.g. influenza, acute respiratory viral infections incl. COVID-19) less than 4 weeks before the first IMP administration.
7. The presence of any other condition which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.
8. Surgery on the gastrointestinal tract (except appendectomy).
9. Deviations from the normal parameters in clinical blood count analysis, biochemical blood analysis, urinalysis.
10. History or presence of orthostatic hypotension or syncope.
11. Systolic blood pressure measured in a sitting position, less than 100 mmHg or above 130 mmHg and/or diastolic blood pressure below 60 mmHg or above 89 mmHg.
12. Heart rate less than 60 or more than 80 beats per minute.
13. Deviation on the ECG intervals and heart rate or ECG morphology.
14. Positive test results for HIV or hepatitis B or C or syphilis at screening.
15. Positive test result for cotinine in the urine at screening or before randomisation.
16. Positive screen for drugs or alcohol at screening or before randomisation.
17. Known or suspected drug or alcohol abuse as judged by the Investigator.
18. Alcohol consumption more than 10 units of alcohol a week (1 unit equivalent to 200 ml of dry wine or 50 ml of strong alcoholic drinks or 500 ml of beer) during the six months prior to the first administration of the IMP.
19. Intake of xanthine containing substances (e.g., coffee, tea, chocolate, energy drinks, cola) as well as citrus fruits (grapefruit, grapefruit juice etc.) and cranberry (including juices, fruit drinks, etc.) within the last 72 hours before the IMP administration.
20. Administration of medicines that have a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazol, cimetidin, NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, diuretics, etc.) less than 2 months or 5 half-lives (whatever is longer) before screening.
21. The use of depot-forms of any drugs for 3 months or 5 half-lives (whatever is longer) before screening.
22. Use of any prescribed or non-prescribed medication, herbal remedies, vitamins and minerals during the two weeks prior to the first administration of the IMP or longer (at least 5 elimination half-lives) if the medication has a long half-life.
23. Mental, physical and other reasons that do not allow the subjects according to investigator's opinion to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort.
24. Dehydration (e.g. due to diarrhea, vomiting, or other causes) within the last 48 hours before the IMP administration.
25. Subjects who have been on a special diet (for whatever reason, e.g. vegetarians or hypocaloric diet [less than 1000 cal/day]) during the 28 days prior to the first IMP administration and intention to maintain the diet during the study.
26. Intention to perform excessive physical activities during the trial.
27. Plasma donation within one month from screening or blood donation/blood loss >500 ml within 3 months before screening.
28. Unwillingness or inability to follow the procedures and restrictions outlined in the protocol and the ICF.
29. Participation in another clinical study within 3 months before the first IMP administration.
30. Difficulty swallowing tablets or fasting or consuming standard meals.
31. Any reason in the opinion of the Investigator, would prevent the subject from participating in the study.
32. Scheduled to have vaccination during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tamsulosin 0.4 mg prolonged-release tablets (Synthon Hispania SL, Spain); Single dose administration (0.4 mg) with 240ml of water under fasting conditions	Drug: Tamsulosin (0.4 mg/j); Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain); Drug: Tamsulosin (0.4 mg/j); Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)
Active Comparator: Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma; Single dose administration (0.4 mg) with 240 ml of water under fasting conditions.	Drug: Tamsulosin (0.4 mg/j); Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain); Drug: Tamsulosin (0.4 mg/j); Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum plasma concentration	72 hours
AUC 0-t	Area under the Plasma Concentration Curve from Administration to Last Observed Concentration at Time t	72 hours
AUC 0-inf	Area under the Plasma Concentration Curve Extrapolated to Infinite Time	Infinity

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tmax	Time to maximum plasma concentration	72 hours
t 1/2	Plasma half-life	72 hours
λz	Terminal Elimination Rate Constant	72 hours
AUC Resid	Residual area	72 hours
AUC 0-24	Area under the plasma concentration curve from time 0 to 24 h	24 hours
partial AUC 0-12	Partial Area under the Plasma Concentration Curve from time 0 to 12 h	12 hours
partial AUC 12-t	Partial Area under the Plasma Concentration Curve from 12 h to Last Observed Concentration at Time t	72 hours

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Analysis of Adverse Events (AEs)	Number (%) of subjects with any AE	21 days
Analysis of Adverse Events (AEs)	Number (%) of subjects with treatment-related AEs	21 days
Analysis of Adverse Events (AEs)	Number (%) of subjects with any Serious Adverse Events (SAEs)	21 days
Analysis of Adverse Events (AEs)	Number (%) of subjects with treatment-related SAEs	21 days
Analysis of Adverse Events (AEs)	Number (%) of subjects discontinued from the study due to AEs	21 days

Collaborators and Investigators

• Sponsor: Berlin-Chemie AG Menarini Group
• Investigators: Principal Investigator: Shougher Heboyan, MD, "Tonus-Les" LLC, 2/1 Varshavyan street. 0037 Yerewan, Armenia

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): September 8, 2025
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: August 27, 2025
• First Submitted That Met QC Criteria: September 4, 2025
• First Posted (Estimated): September 5, 2025

Study Record Updates

• Last Update Posted (Estimated): October 3, 2025
• Last Update Submitted That Met QC Criteria: October 2, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Bioequivalence; Tamsulosin
• Additional Relevant MeSH Terms: Sulfur Compounds; Organic Chemicals; Hydrocarbons; Hydrocarbons, Cyclic; Hydrocarbons, Aromatic; Amides; Benzene Derivatives; Benzenesulfonamides; Sulfonamides; Sulfones; Tamsulosin
• Other Study ID Numbers: BCAM/23/Tam-BE/003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No publication in an ICMJE journal is planned

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No